Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of “Buy” from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $147.50.

A number of analysts have issued reports on the company. Mizuho lifted their price target on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Jefferies Financial Group boosted their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. BTIG Research upped their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Leerink Partners raised their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Finally, Needham & Company LLC upped their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,479,005.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Vaxcyte news, COO Jim Wassil sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total transaction of $1,119,300.00. Following the completion of the sale, the chief operating officer now directly owns 207,503 shares of the company’s stock, valued at approximately $23,225,810.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,479,005.02. The disclosure for this sale can be found here. Insiders have sold 71,000 shares of company stock worth $6,508,130 in the last quarter. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently modified their holdings of the stock. Principal Financial Group Inc. increased its stake in Vaxcyte by 1.7% in the 4th quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock valued at $1,382,000 after buying an additional 376 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Vaxcyte by 25.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company’s stock worth $439,000 after acquiring an additional 1,411 shares during the period. UBS Group AG raised its holdings in Vaxcyte by 123.4% during the fourth quarter. UBS Group AG now owns 166,034 shares of the company’s stock worth $10,427,000 after purchasing an additional 91,729 shares in the last quarter. Orion Portfolio Solutions LLC lifted its position in Vaxcyte by 16.8% in the fourth quarter. Orion Portfolio Solutions LLC now owns 7,305 shares of the company’s stock valued at $443,000 after purchasing an additional 1,050 shares during the period. Finally, Parallel Advisors LLC lifted its position in Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Down 1.1 %

Shares of NASDAQ:PCVX opened at $114.25 on Friday. Vaxcyte has a fifty-two week low of $44.20 and a fifty-two week high of $121.06. The firm’s 50 day moving average price is $94.05 and its 200 day moving average price is $78.76. The stock has a market cap of $12.75 billion, a price-to-earnings ratio of -26.69 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter last year, the business earned ($0.70) earnings per share. On average, equities analysts anticipate that Vaxcyte will post -4.33 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.